New targeted drug MBRC-101 enters human trials for Hard-to-Treat cancers
NCT ID NCT06014658
First seen Mar 06, 2026 · Last updated Jun 15, 2026 · Updated 20 times
Summary
This study tests a new drug called MBRC-101 in people with advanced solid tumors that have not responded to standard therapies. The drug is designed to deliver a chemotherapy-like agent directly to cancer cells. The trial has three parts: first, finding the safest and most effective dose; second, checking safety and early signs of benefit; and third, measuring how well the drug works. About 130 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Carolina BioOncology Institute
ACTIVE_NOT_RECRUITINGHuntersville, North Carolina, 28078, United States
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact
-
Comprehensive Cancer Center of Nevada
RECRUITINGLas Vegas, Nevada, 89169, United States
Contact
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
Contact
-
Horizon Oncology Research
COMPLETEDLafayette, Indiana, 47905, United States
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
-
Medical University of South Carolina (MUSC)
RECRUITINGCharleston, South Carolina, 29425, United States
Contact
-
NEXT Oncology
RECRUITINGAustin, Texas, 78758, United States
Contact
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
Contact
-
NEXT Oncology
RECRUITINGFairfax, Virginia, 22031, United States
Contact
-
PRISMA Health, Institute for Translational Oncology
RECRUITINGGreenville, South Carolina, 29605, United States
Contact
-
Rutgers Cancer Institute of New Jersey
RECRUITINGNew Brunswick, New Jersey, 08903, United States
Contact
Contact
-
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94158, United States
Contact
Contact Email: •••••@•••••
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
-
University of Colorado, Anschutz Cancer Pavilion (ACP(
RECRUITINGAurora, Colorado, 80045, United States
Contact
-
University of Pennsylvania, Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19014, United States
Contact
-
Winship Cancer Institute, Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.